Sat, Dec 20, 2014, 10:27 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

DepoMed Inc. Message Board

  • jpm2042 jpm2042 Feb 6, 2012 8:20 AM Flag

    TM...scripts?

    Hey tm ..do you have the scripts for this week?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • n This week's data. New and total prescriptions for Gralise were 1,777 and
      2,488 (versus 1,624 and 2,242 last week - holiday shortened week). At ~
      $150/script, this translates into a ~$19.4 million annualized run rate. Total
      share of gabapentin-like products increased to 0.28% from 0.27%. The
      product was launched in October 2011. We view this week's Gralise data
      as neutral post the bounce to a new high in total prescriptions following the
      Memorial Day holiday on May 28th. Prescription trends are on track with our
      target of 2,700 per week by the end of June. The 4-week moving average
      increased to 46, which is slightly below our ~60 weekly target.

    • WOW GREAT

    • Week of 6/8: 2,488 total

      Up 11% week/week!

    • This week's data. New and total prescriptions for Gralise were 1,624 and
      2,242 (versus 1,675 and 2,271 last week). At ~$150/script, this translates
      into a ~$17.5 million annualized run rate (company recently upped price
      by ~20%). Total share of gabapentin-like products was flat at 0.27%. The
      product was launched in October 2011. We view this week's Gralise data as
      mostly noise given the disruption of the Memorial Day holiday on May 28th.
      As a result of this noise, the 4-week moving average dipped below our ~60
      weekly target. We expect a significant uptick next week.

    • Includes record high refills, #596

    • This week's data. New and total prescriptions for Gralise were 1,675 and
      2,271 (versus 1,662 and 2,213 last week). At ~$150/script, this translates
      into a ~$17.7 million annualized run rate (company recently upped price
      by ~20%). Total share of gabapentin-like products was flat at 0.27%. The
      product was launched in October 2011. We view this week's Gralise data
      as neutral given a modest increase over the prior week. The 4-week moving
      average of 56 remains near our ~60 weekly target.

    • This week's data. New and total prescriptions for Gralise were 1,662 and
      2,213 (versus 1,745 and 2,303 last week). At ~$150/script, this translates
      into a ~$17.3 million annualized run rate (company recently upped price
      by ~20%). Total share of gabapentin-like products was flat at 0.27%. The
      product was launched in October 2011. We view this week's Gralise data
      as neutral given a small decline after multiple strong weeks. As a result of
      this negative variance, the 4-week moving average dipped below our ~60
      weekly target.

    • Thanks. Another great week.

    • This week's data. New and total prescriptions for Gralise were 1,745 and
      2,303 (versus 1,690 and 2,197 last week). At ~$150/script, this translates
      into a ~$18.0 million annualized run rate (company recently upped price by
      ~20%). Total share of gabapentin-like products increased to 0.27%, versus
      0.24% last week. The product was launched in October 2011. We view
      this week's Gralise data as positive given a 106 prescription gain. More
      importantly, the 4-week moving average for prescription gains of 79 remains
      above our ~60 weekly target.

      • 3 Replies to better_yeti
      • Thanks for the graph. They need to hit over 3,000 scripts just to cover the monthly sales group cost. I have no knowledge of drug sales ramp up but the graph looks promising. doc

      • better_yeti,
        Much obliged for the graph that puts into one visual the impressive gains being made for Gralise Rx's. I'd love to know which database (of PHN specialists) the sales reps are running off of, and whether they are yet moving outside of that 'comfort zone' for additional Rx's.

        Translation: at what point do the reps grab the low hanging fruit and then start looking up higher in the tree (for the more difficult Rx's)?

        Too bad we don't have a fly on the wall at the next sales rep annual meeting to hear their presentations of how it's going in the field. Getting such intel often yields pointers to trading DEPO. (e.g., Rx's coming more easily -- buy; Rx's getting harder to nail down -- hold).

      • Thank you for sharing the impressive Gralise chart, maybe some day the stock price chart will look the same :)

    • View More Messages
 
DEPO
16.24+0.52(+3.31%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Under Armour, Inc.
NYSEFri, Dec 19, 2014 4:04 PM EST
ImmunoGen, Inc.
NASDAQFri, Dec 19, 2014 4:00 PM EST
Southwestern Energy Co.
NYSEFri, Dec 19, 2014 4:05 PM EST